Vitamin c and immunotherapy combo trial for lung cancer ends early after just one patient

NCT ID NCT06083454

Terminated Disease control Sponsor: William Zeitler Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This very early trial aimed to see if adding high-dose vitamin C to the immunotherapy drug durvalumab could boost the immune response against non-small cell lung cancer before surgery. It planned to enroll people with early-stage lung cancer, but was terminated after only one participant. Because it stopped so early, we cannot draw any meaningful conclusions about safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: high-dose vitamin C (pharmacological ascorbate) and durvalumab (an immunotherapy drug)
What this could lead to: If it had worked, this could have pointed toward a way to boost the immune system's attack on lung cancer before surgery.
What could go wrong: The trial was very early (Phase 1) and was terminated after enrolling just 1 person, so we have almost no data. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

University of Iowa

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.